Market Intelligence, Clinical Progress, and High-Purity Reagents for Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BTN1A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTN1A1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View BTN1A1 Products |
| Gene Delivery | BTN1A1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Codon-optimized for high expression. |
View BTN1A1 Products |
| Benchmark Ab | Anti-BTN1A1 (Research Grade / Nelitolimab Sequence) Recombinant positive control for binding assays. |
View BTN1A1 Products |
| Validator | BTN1A1 siRNA Set For knockdown verification and specificity confirmation. |
View BTN1A1 Products |
| Related Target A | BTN2A1 Butyrophilin family member; critical phosphoantigen co-regulator with BTN1A1. |
View BTN2A1 Products |
| Related Target B | BTN3A1 (CD277) Structural homolog; essential for γδ T cell activation pathway cross-talk. |
View BTN3A1 Products |
| Related Target C | PD-L1 Orthogonal checkpoint often mutually exclusive with BTN1A1 expression. |
View PD-L1 Products |
| Related Target D | TIGIT Synergistic exhaustion marker for combination therapy rationale. |
View TIGIT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Butyrophilin Family Cross-Reactivity (BTN1A1 vs BTN2A1 vs BTN3A1) | Homolog Panel Proteins strictly verified by Mass Spec; >95% purity with distinct ECD domain boundaries |
| Cross-species Cyno/Mouse Evaluations | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence identity verified |
| Lack of Conformational Controls | Full-length Lentivirus particles for native membrane presentation; Sequence Verified ORF |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; Endotoxin Controlled (<1 EU/µg) |
| Lack of Clinical Benchmark Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation |
Live BTN1A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BTN1A1 therapeutics is intensifying, with major players shifting focus from traditional PD-1/PD-L1 pathways to novel butyrophilin family checkpoints. As an emerging immune checkpoint that is mutually exclusive with PD-L1 in many tumor microenvironments, BTN1A1 offers a critical bypass mechanism for PD-1/PD-L1 refractory patients. First-generation candidates like Nelitolimab (HiFiBiO Therapeutics) are advancing clinically. The next wave of R&D is targeting BTN1A1-BTN2A1 heteromeric complexes, bispecific engagers, and pH-dependent conformational states.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb (Naked) | HiFiBiO Therapeutics, Emerging Biotech | Solid Tumors (γδ T cell infiltration; PD-L1 negative) | Epitope Mapping & Binding Affinity (Need full-length Lentivirus for native conformation and high-purity ECD-Fc) |
| Bispecific Engager | Immuno-Oncology Focused, Preclinical Biotech | Hematological Malignancies, Immunotherapy | Heterodimer Validation (Need BTN1A1/BTN2A1 cross-reactive panels and cross-reactive Abs) |
| Cell Therapy (CAR-γδ) | Cell Therapy Innovators | Refractory Cancers | Stable Cell Line Construction (High-titer Lentivirus with puromycin selection) |
| ADC (Future) | Emerging Innovators | Refractory Cancers | Internalization Assay (Need Lentivirus for Cell Lines) |
Molecular Characteristics (UniProt Q13410)
- Functional Domains: Ig-like V-type 1, Ig-like V-type 2, B30.2/SPRY
- Key Mutations (dbSNP): rs3736781, rs1980600, rs9393728